New: Introducing “Why Is It Moving?” - lightning-fast, AI-driven explanations of stock moves

Learn More
Last Close
Oct 17  •  04:00PM ET
4.08
Dollar change
-0.05
Percentage change
-1.21
%
IndexRUT P/E- EPS (ttm)-1.57 Insider Own21.64% Shs Outstand112.50M Perf Week-7.69%
Market Cap459.00M Forward P/E- EPS next Y-1.30 Insider Trans0.00% Shs Float88.15M Perf Month20.35%
Enterprise Value645.21M PEG- EPS next Q-0.36 Inst Own58.97% Short Float6.01% Perf Quarter29.94%
Income-169.94M P/S5.94 EPS this Y6.17% Inst Trans4.64% Short Ratio6.29 Perf Half Y237.19%
Sales77.25M P/B- EPS next Y14.47% ROA-49.02% Short Interest5.30M Perf YTD105.03%
Book/sh-1.77 P/C1.73 EPS next 5Y19.09% ROE- 52W High4.74 -13.92% Perf Year35.55%
Cash/sh2.35 P/FCF- EPS past 3/5Y18.47% 1.38% ROIC-68.03% 52W Low1.05 288.57% Perf 3Y-5.12%
Dividend Est.- EV/EBITDA- Sales past 3/5Y27.82% 97.79% Gross Margin89.18% Volatility7.79% 6.99% Perf 5Y-88.15%
Dividend TTM- EV/Sales8.35 EPS Y/Y TTM38.73% Oper. Margin-165.08% ATR (14)0.27 Perf 10Y-
Dividend Ex-Date- Quick Ratio4.66 Sales Y/Y TTM15.73% Profit Margin-220.00% RSI (14)53.52 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio4.93 EPS Q/Q-30.40% SMA200.64% Beta1.96 Target Price8.00
Payout- Debt/Eq- Sales Q/Q8.21% SMA5015.29% Rel Volume0.87 Prev Close4.13
Employees265 LT Debt/Eq- EarningsAug 12 BMO SMA20065.97% Avg Volume842.48K Price4.08
IPOMay 15, 2020 Option/ShortYes / Yes EPS/Sales Surpr.-1.63% 5.48% Trades Volume734,244 Change-1.21%
Date Action Analyst Rating Change Price Target Change
Nov-08-24Initiated Stephens Overweight $6
May-30-24Initiated Cantor Fitzgerald Overweight
Mar-28-24Initiated Guggenheim Buy $11
Aug-10-23Upgrade JP Morgan Underweight → Neutral
Apr-24-23Downgrade BofA Securities Neutral → Underperform $7 → $2
Dec-06-22Initiated CapitalOne Overweight $12
Nov-09-22Downgrade BofA Securities Buy → Neutral $14 → $7
Sep-21-22Initiated JP Morgan Overweight $5
Sep-09-22Downgrade Morgan Stanley Overweight → Equal-Weight $17 → $11
Nov-09-21Initiated Wolfe Research Outperform $44
Oct-13-25 01:06PM
07:30AM
Oct-01-25 04:05PM
Sep-29-25 12:56AM
Sep-18-25 10:34AM
04:05PM Loading…
Sep-02-25 04:05PM
Aug-27-25 07:15AM
Aug-13-25 03:07AM
Aug-12-25 03:00PM
07:30AM
Aug-11-25 07:00PM
09:34AM
Aug-07-25 06:10PM
Aug-05-25 04:05PM
Aug-04-25 09:40AM
04:05PM Loading…
Aug-01-25 04:05PM
Jul-01-25 04:05PM
Jun-26-25 11:44AM
Jun-16-25 07:15AM
Jun-12-25 06:45AM
06:30AM
Jun-02-25 04:05PM
May-30-25 05:44AM
May-15-25 07:49AM
07:15AM
May-14-25 09:10AM
08:00AM
07:45AM
May-13-25 09:42AM
May-08-25 05:50PM
07:15AM Loading…
07:15AM
May-01-25 05:25PM
Apr-30-25 08:15AM
Apr-29-25 10:01AM
Apr-28-25 10:00AM
07:00AM
Apr-01-25 04:05PM
07:15AM
Mar-31-25 09:00PM
Mar-27-25 11:17AM
08:35AM
07:30AM
Mar-25-25 05:30PM
Mar-24-25 11:08PM
Mar-20-25 07:15AM
Feb-03-25 04:05PM
Jan-30-25 07:15AM
Jan-02-25 04:05PM
Dec-30-24 04:30PM
Dec-11-24 07:30AM
Dec-09-24 07:30AM
Dec-06-24 07:30AM
Dec-02-24 04:30PM
Nov-14-24 02:02AM
Nov-08-24 01:14PM
Nov-07-24 08:50AM
07:30AM
Nov-06-24 07:41AM
Nov-05-24 09:47AM
Nov-04-24 07:15AM
Nov-01-24 04:05PM
09:40AM
Oct-31-24 07:15AM
Oct-01-24 04:05PM
Sep-03-24 04:05PM
07:15AM
Aug-06-24 08:40AM
07:30AM
Aug-01-24 04:05PM
Jul-30-24 07:15AM
Jul-11-24 03:24PM
Jul-08-24 02:00AM
Jul-01-24 04:05PM
Jun-27-24 07:15AM
Jun-13-24 02:31PM
Jun-03-24 04:05PM
May-30-24 07:15AM
May-15-24 07:15AM
May-09-24 07:01PM
07:15AM
May-07-24 08:55AM
08:44AM
May-06-24 10:53AM
08:22AM
07:30AM
07:20AM
06:55AM
06:10AM
06:00AM
May-01-24 04:05PM
07:00AM
Apr-16-24 08:30AM
Apr-04-24 07:00AM
Apr-03-24 07:00AM
Apr-01-24 04:05PM
Mar-15-24 12:30PM
Mar-14-24 05:16AM
Mar-13-24 08:51AM
08:20AM
07:00AM
ADC Therapeutics SA is a clinical-stage biotechnology company, which engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its clinical-stage product candidates include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Redmile Group, LLC10% OwnerDec 11 '24Buy3.04100,000304,50015,666,731Dec 13 09:00 PM
Redmile Group, LLC10% OwnerDec 11 '24Buy3.04100,000304,50013,145,712Dec 13 09:00 PM
Redmile Group, LLC10% OwnerDec 04 '24Sale2.0725,35252,47915,566,731Dec 06 09:00 PM